Altered astrocytic response to activation in SOD1G93A mice and its implications on amyotrophic lateral sclerosis pathogenesis

GLIA

Volumn 61, Issue 3, 2013, Pages 312-326

  Benkler, Chen ^a   Ben Zur, Tali ^a   Barhum, Yael ^a   Offen, Daniel ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

ALS; EAAT2; GLT1; Glutamate; Motor neurons; Neurotrophic factor; Reactive astrocytes

Indexed keywords

ALANINE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTAMIC ACID; GLYCINE; LIPOPOLYSACCHARIDE; VESICULAR GLUTAMATE TRANSPORTER 1;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; ASTROCYTE; CELL LINE; ENZYME ACTIVATION; MOUSE; NERVE DEGENERATION; NEWBORN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ASTROCYTES; CEFTRIAXONE; CELL DIFFERENTIATION; CELLS, CULTURED; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; LIPOPOLYSACCHARIDES; MICE; MICE, TRANSGENIC; SUPEROXIDE DISMUTASE; UP-REGULATION;

EID: 84872620215     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22428     Document Type: Article

References (118)

1. Apricò K, Beart P, Crawford D, O'Shea R. 2004. Binding and transport of [3H](2S, 4R)-4-methylglutamate, a new ligand for glutamate transporters, demonstrate labeling of EAAT1 in cultured murine astrocytes. J Neurosci Res 75: 751-759.
2. Audet JN, Gowing G, Julien JP. 2010. Wild-type human SOD1 overexpression does not accelerate motor neuron disease in mice expressing murine Sod1 G86R. Neurobiol Dis 40: 245-250.
3. Barbeito L, Pehar M, Cassina P, Vargas M, Peluffo H, Viera L, Estévez AG, Beckman JS. 2004. A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res Brain Res Rev 47: 263-274.
4. Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, Yen AA, Siklos L, McKercher SR, Appel SH. 2006. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 103: 16021-16026.
5. Bendotti C, Tortarolo M, Suchak S, Calvaresi N, Carvelli L, Bastone A, Rizzi M, Rattray M, Mennini T. 2001. Transgenic SOD1 G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. J Neurochem 79: 737-746.
6. Benkler C, Offen D, Melamed E, Kupershmidt L, Amit T, Mandel S, Youdim MBH, Weinreb O. 2010. Recent advances in amyotrophic lateral sclerosis research: Perspectives for personalized clinical application. EPMA 1: 343-361.
7. Bilsland LG, Nirmalananthan N, Yip J, Greensmith L, Duchen MR. 2008. Expression of mutant SOD1 in astrocytes induces functional deficits in motoneuron mitochondria. J Neurochem 107: 1271-1283.
8. Bogaert E, d'Ydewalle C, Van Den Bosch L. 2010. Amyotrophic lateral sclerosis and excitotoxicity: From pathological mechanism to therapeutic target. CNS Neurol Disord Drug Targets 9: 297-304.
9. Boillée S, Vande Velde C, Cleveland DW. 2006. ALS: A disease of motor neurons and their nonneuronal neighbors. Neuron 52: 39-59.
10. Borchelt D, Lee M, Slunt H, Guarnieri M, Xu Z, Wong P, Brown R, Price D, Sisodia S, Cleveland D. 1994. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc Natl Acad Sci USA 91: 8292-8296.
11. Bos I, Hoogland G, Meine Jansen C, Willigen G, Spierenburg H, van den Berg L, de Graan PN. 2006. Increased glutamine synthetase but normal EAAT2 expression in platelets of ALS patients. Neurochem Int 48: 306-311.
12. Boucherie C, Caumont A, Maloteaux J, Hermans E. 2008. In vitro evidence for impaired neuroprotective capacities of adult mesenchymal stem cells derived from a rat model of familial amyotrophic lateral sclerosis (hSOD1(G93A)). Exp Neurol 212: 557-561.
13. Cashman N, Durham H, Blusztajn J, Oda K, Tabira T, Shaw I, Dahrouge S, Antel JP. 1992. Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev Dyn 194: 209-221.
14. Cassina P, Peluffo H, Pehar M, Martinez-Palma L, Ressia A, Beckman JS, Estévez AG, Barbeito L. 2002. Peroxynitrite triggers a phenotypic transformation in spinal cord astrocytes that induces motor neuron apoptosis. J Neurosci Res 67: 21-29.
15. Cassina P, Pehar M, Vargas M, Castellanos R, Barbeito A, Estévez A, Thompson JA, Beckman JS, Barbeito L. 2005. Astrocyte activation by fibroblast growth factor-1 and motor neuron apoptosis: Implications for amyotrophic lateral sclerosis. J Neurochem 93: 38-46.
16. Charles T, Swash M. 2001. Amyotrophic lateral sclerosis: Current understanding. J Neurosci Nurs 33: 245-253.
17. Chattopadhyay M, Valentine JS. 2009. Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. Antioxid Redox Signal 11: 1603-1614.
18. Chiu A, Zhai P, Dal Canto M, Peters T, Kwon Y, Prattis S, Gurney M. 1995. Age dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol Cell Neurosci 6: 349-362.
19. Chung I, Benveniste E. 1990. Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta. J Immunol 144: 2999-3007.
20. Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillée S, Rule M, McMahon AP, Doucette W, Siwek D, Ferrante RJ, Brown RHJr, Julien JP, Goldstein LS, Cleveland DW. 2003. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302: 113-117.
21. Cleveland D, Rothstein J. 2001. From Charcot to Lou Gehrig: Deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2: 806-819.
22. Dal Canto M, Gurney M. 1995. Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu, Zn SOD, and in mice overexpressing wild type human SOD: A model of familial amyotrophic lateral sclerosis (FALS). Brain Res 3; 676: 25-40.
23. Danbolt N. 2001. Glutamate uptake. Prog Neurobiol 65: 1-105.
24. Dawbarn D, Allen SJ. 2003. Neurotrophins and neurodegeneration. Neuropathol Appl Neurobiol 29: 211-230.
25. De Lanerolle NC, Lee TS, Spencer DD. 2010. Astrocytes and epilepsy. Neurotherapeutics 7: 424-438.
26. Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K. 2007. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci 10: 608-611.
27. Doble A. 1999. The role of excitotoxicity in neurodegenerative disease: Implications for therapy. Pharmacol Ther 81: 163-221.
28. Dunlop J, Beal McIlvain H, She Y, Howland D. 2003. Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J Neurosci 23: 1688-1696.
29. Eddleston M, Mucke L. 1993. Molecular profile of reactive astrocytes-Implications for their role in neurologic disease. Neuroscience 54: 15-36.
30. Eggett C, Crosier S, Manning P, Cookson M, Menzies F, McNeil C, Shaw PJ. 2000. Development and characterisation of a glutamate-sensitive motor neurone cell line. J Neurochem 74: 1895-1902.
31. Ekestern E. 2004. Neurotrophic factors and amyotrophic lateral sclerosis. Neurodegener Dis 1: 88-100.
32. Falsig J, Pörzgen P, Lund S, Schrattenholz A, Leist M. 2006. The inflammatory transcriptome of reactive murine astrocytes and implications for their innate immune function. J Neurochem 96: 893-907.
33. Faulkner J, Herrmann J, Woo M, Tansey K, Doan N, Sofroniew M. 2004. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 24: 2143-2155.
34. Ferraiuolo L, Higginbottom A, Heath PR, Barber S, Greenald D, Kirby J, Shaw PJ. 2011. Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis. Brain 134: 2627-2641.
35. Figiel M, Maucher T, Rozyczka J, Bayatti N, Engele J. 2003. Regulation of glial glutamate transporter expression by growth factors. Exp Neurol 183: 124-135.
36. Fischer I, Alliod C, Martinier N, Newcombe J, Brana C, Pouly S. 2011. Sphingosine kinase 1 and sphingosine 1-phosphate receptor 3 are functionally upregulated on astrocytes under pro-inflammatory conditions. PLoS One. 6: e23905.
37. Foran E, Trotti D. 2009. Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid Redox Signal 11: 1587-1602.
38. Forsberg K, Andersen PM, Marklund SL, Brännström T. 2011. Glial nuclear aggregates of superoxide dismutase-1 are regularly present in patients with amyotrophic lateral sclerosis. Acta Neuropathol 121: 623-634.
39. Forsberg K, Jonsson PA, Andersen PM, Bergemalm D, Graffmo KS, Hultdin M, Jacobsson J, Rosquist R, Marklund SL, Brännström T. 2010. Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS One 5: e11552.
40. Fray A, Dempster S, Williams R, Cookson M, Shaw P. 2001. Glutamine synthetase activity and expression are not affected by the development of motor neuronopathy in the G93A SOD-1/ALS mouse. Brain Res Mol Brain Res 94: 131-136.
41. Garcia-Estrada J, Garcia-Segura L, Torres-Aleman I. 1992. Expression of insulin-like growth factor I by astrocytes in response to injury. Brain Res 592: 343-347.
42. Giménez y Ribotta M, Revah F, Pradier L, Loquet I, Mallet J, Privat A. 1997. Prevention of motoneuron death by adenovirus-mediated neurotrophic factors. J Neurosci Res 48: 281-285.
43. Gould T, Oppenheim R. 2011. Motor neuron trophic factors: Therapeutic use in ALS? Brain Res Rev 67: 1-39.
44. Guo Y, Li C, Wu D, Wu S, Yang C, Liu Y, Wu H, Li Z. 2010. Ultrastructural diversity of inclusions and aggregations in the lumbar spinal cord of SOD1-G93A transgenic mice. Brain Res 1353: 234-244.
45. Gurney M, Pu H, Chiu A, Dal Canto M, Polchow C, Alexander D, Caliendo J, Hentati A, Kwon YW, Deng HX, Chen W, Zhai P, Sufit RL, Sidd T. 1994. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264: 1772-1775.
46. Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, Frakes A, Song S, Likhite S, Murtha MJ, Foust KD, Rao M, Eagle A, Kammesheidt A, Christensen A, Mendell JR, Burghes AH, Kaspar BK. 2011. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 29: 824-828.
47. Hamby M, Sofroniew M. 2010. Reactive astrocytes as therapeutic targets for CNS disorders. Neurotherapeutics 7: 494-506.
48. Hedlund E, Isacson O. 2008. ALS model glia can mediate toxicity to motor neurons derived from human embryonic stem cells. Cell Stem Cell 3: 575-576.
49. Hensley K, Abdel-Moaty H, Hunter J, Mhatre M, Mou S, Nguyen K, Potapova T, Pye QN, Qi M, Rice H, Stewart C, Stroukoff K, West M. 2006. Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. J Neuroinflammation 25;3: 2.
50. Hertz L. 1979. Functional interactions between neurons and astrocytes I. Turnover and metabolism of putative amino acid transmitters. Prog Neurobiol 13: 277-323.
51. Holst O, Ulmer A, Brade H, Flad H, Rietschel E. 1996. Biochemistry and cell biology of bacterial endotoxins. FEMS Immunol Med Microbiol 16: 83-104.
52. Howland D, Liu J, She Y, Goad B, Maragakis N, Kim B, Erickson J, Kulik J, DeVito L, Psaltis G, DeGennaro LJ, Cleveland DW, Rothstein JD. 2002. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci USA 99: 1604-1609.
53. Ilieva H, Polymenidou M, Cleveland D. 2009. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 187: 761-772.
54. Kim H, Kim HY, Choi M, Hwang S, Nam K, Kim H, Han JS, Kim KS, Yoon HS, Kim SH. 2010. Dose-dependent efficacy of ALS-human mesenchymal stem cells transplantation into cisterna magna in SOD1-G93A ALS mice. Neurosci Lett 468: 190-194.
55. Kuno R, Yoshida Y, Nitta A, Nabeshima T, Wang J, Sonobe Y, Kawanokuchi J, Takeuchi H, Mizuno T, Suzumura A. 2006. The role of TNF-alpha and its receptors in the production of NGF and GDNF by astrocytes. Brain Res 1116: 12-18.
56. Lalonde R, Dumont M, Paly E, London J, Strazielle C. 2004. Characterization of hemizygous SOD1/wild-type transgenic mice with the SHIRPA primary screen and tests of sensorimotor function and anxiety. Brain Res Bull 64: 251-258.
57. Lasiene J, Yamanaka K. 2011. Glial cells in amyotrophic lateral sclerosis. Neurol Res Int 2011: 1-7.
58. Lee M, Deller T, Kirsch M, Frotscher M, Hofmann H. 1997. Differential regulation of ciliary neurotrophic factor (CNTF) and CNTF receptor alpha expression in astrocytes and neurons of the fascia dentata after entorhinal cortex lesion. J Neurosci 17: 1137-1146.
59. Lee M, Kim C, Shin S, Moon S, Chun M. 1998. Increased ciliary neurotrophic factor expression in reactive astrocytes following spinal cord injury in the rat. Neurosci Lett 255: 79-82.
60. Lee S, Su Z, Emdad L, Gupta P, Sarkar D, Borjabad A, Volsky DJ, Fisher PB. 2008. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J Biol Chem 283: 13116-13123.
61. Lepore A, Rauck B, Dejea C, Pardo A, Rao M, Rothstein J, Maragakis NJ. 2008. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat Neurosci 11: 1294-1301.
62. Lin CL, Bristol LA, Jin L, Dykes-Hoberg M, Crawford T, Clawson L, Rothstein JD. 1998. Aberrant RNA processing in a neurodegenerative disease: The cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 20: 589-602.
63. Lin S, Wang Y, Xue Y, Feng D, Xu Y, Xu L. 2008. Tetrandrine suppresses LPS-induced astrocyte activation via modulating IKKs-IkappaBalpha-NF-kappaB signaling pathway. Mol Cell Biochem 315: 41-49.
64. Lipton S, Rosenberg P. 1994. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 330: 613-622.
65. Maragakis N, Rothstein J. 2001. Glutamate transporters in neurologic disease. Arch Neurol 58: 365-370.
66. Maragakis N, Rothstein J. 2006. Mechanisms of disease: Astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2: 679-689.
67. Mattson M. 2008. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann NY Acad Sci 1144: 97-112.
68. Matusica D, Fenech M, Rogers M, Rush R. 2008. Characterization and use of the NSC-34 cell line for study of neurotrophin receptor trafficking. J Neurosci Res 86: 553-565.
69. Michler-Stuke A, wolff J, Bottenstein J. 1984. Factors influencing astrocyte growth and development in defined media. Int J Dev Neurosci 2: 575-584.
70. Millecamps S, Boillée S, Le Ber I, Seilhean D, Teyssou E, Giraudeau M, Moigneu C, Vandenberghe N, Danel-Brunaud V, Corcia P, Pradat PF, Le Forestier N, Lacomblez L, Bruneteau G, Camu W, Brice A, Cazeneuve C, Leguern E, Meininger V, Salachas F. 2012. Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J Med Genet 49: 258-263.
71. Mohajeri M, Figlewicz D, Bohn M. 1999. Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis. Hum Gene Ther 10: 1853-1866.
72. Molz S, Decker H, Dal-Cim T, Cremonez C, Cordova F, Leal R, Tasca CI. 2008. Glutamate-induced toxicity in hippocampal slices involves apoptotic features and p38 MAPK signaling. Neurochem Res 33: 27-36.
73. Myer DJ, Gurkoff GG, Lee SM, Hovda DA, Sofroniew MV. 2006. Essential protective roles of reactive astrocytes in traumatic brain injury. Brain 129: 2761-2772.
74. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, Przedborski S. 2007. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 10: 615-622.
75. Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, Haigh J, Malta E, Traub M, Sendtner M, Toyka KV. 2000. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1: 201-206.
76. Okada K, Yamashita U, Tsuji S. 2005. Modulation of Na(+)-dependent glutamate transporter of murine astrocytes by inflammatory mediators. J UOEH 27: 161-170.
77. Oliveira A, Pereira R. 2009. Amyotrophic lateral sclerosis (ALS): Three letters that change the people's life. For ever. Arq Neuropsiquiatr. 67: 750-782.
78. O'Shea R, Lau C, Farso M, Diwakarla S, Zagami C, Svendsen B, Feeney SJ, Callaway JK, Jones NM, Pow DV, Danbolt NC, Jarrott B, Beart PM. 2006. Effects of lipopolysaccharide on glial phenotype and activity of glutamate transporters: Evidence for delayed up-regulation and redistribution of GLT-1. Neurochem Int 48: 604-610.
79. Oyesiku NM, Wilcox JN, Wigston DJ. 1997. Changes in expression of ciliary neurotrophic factor (CNTF) and CNTF-receptor alpha after spinal cord injury. J Neurobiol 32: 251-261.
80. Pekny M, Nilsson M. 2005. Astrocyte activation and reactive gliosis. Glia 50: 427-434.
81. Persson M, Brantefjord M, Hansson E, Rönnbäck L. 2005. Lipopolysaccharide increases microglial GLT-1 expression and glutamate uptake capacity in vitro by a mechanism dependent on TNF-alpha. Glia 51: 111-220.
82. Polymenidou M, Lagier-Tourenne C, Hutt KR, Bennett CF, Cleveland DW, Yeo GW. 2012. Misregulated RNA processing in amyotrophic lateral sclerosis. Brain Res 1462: 3-15.
83. Reaume A, Elliott J, Hoffman E, Kowall N, Ferrante R, Siwek D, Wilcox H, Flood D, Beal M, Brown R, Scott R, Snider W. 1996. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 13: 43-47.
84. Ripps M, Huntley G, Hof P, Morrison J, Gordon J. 1995. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 92: 689-693.
85. Rothstein J, Martin L, Kuncl R. 1992. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 22: 1464-1468.
86. Rothstein J, Van Kammen M, Levey A, Martin L, Kuncl R. 1995. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38: 73-84.
87. Rothstein J, Dykes-Hoberg M, Pardo C, Bristol L, Jin L, Kuncl R, Kanai Y, Hediger MA, Wang Y, Schielke JP, Welty DF. 1996. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16: 675-686.
88. Rothstein J, Patel S, Regan M, Haenggeli C, Haenggeli C, Huang Y, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB. 2005. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433: 73-77.
89. Sakowski SA, Schuyler AD, Feldman EL. 2009. Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 10: 63-73.
90. Sasaki S, Komori T, Iwata M. 2000. Excitatory amino acid transporter 1 and 2 immunoreactivity in the spinal cord in amyotrophic lateral sclerosis. Acta Neuropathol 100: 138-144.
91. Sato Y, Chin Y, Kato T, Tanaka Y, Tozuka Y, Mase M, Ageyama N, Ono F, Terao K, Yoshikawa Y, Hisatsune T. 2009. White matter activated glial cells produce BDNF in a stroke model of monkeys. Neurosci Res 65: 71-78.
92. Saura J. 2007. Microglial cells in astroglial cultures: A cautionary note. J Neuroinflammation 15;4: 26.
93. Schlag B, Vondrasek J, Munir M, Kalandadze A, Zelenaia O, Rothstein J, Robinson MB. 1998. Regulation of the glial Na+-dependent glutamate transporters by cyclic AMP analogs and neurons. Mol Pharmacol 53: 355-369.
94. Scorisa JM, Duobles T, Oliveira GP, Maximino JR, Chadi G. 2010. The review of the methods to obtain non-neuronal cells to study glial influence on Amyotrophic Lateral Sclerosis pathophysiology at molecular level in vitro. Acta Cir Bras 25: 281-289.
95. Seifert G, Carmignoto G, Steinhäuser C. 2010. Astrocyte dysfunction in epilepsy. Brain Res Rev 63: 212-221.
96. Sendtner M, Kreutzberg GW, Thoenen H. 1990. Ciliary neurotrophic factor prevents the degeneration of motor neurons after axotomy. Nature 345: 440-441.
97. Shaw P, Ince P. 1997. Glutamate, excitotoxicity and amyotrophic lateral sclerosis. J Neurol 2: S3-S14.
98. Skaper S, Facci L, Leon A. 1995. Inflammatory mediator stimulation of astrocytes and meningeal fibroblasts induces neuronal degeneration via the nitridergic pathway. J Neurochem 64: 266-276.
99. Sonnewald U, Qu H, Aschner M. 2002. Pharmacology and toxicology of astrocyte-neuron glutamate transport and cycling. J Pharmacol Exp Ther 301: 1-6.
100. Staats K, Van Den Bosch L. 2009. Astrocytes in amyotrophic lateral sclerosis: Direct effects on motor neuron survival. J Biol Phys 35: 337-346.
101. Suzuki M, McHugh J, Tork C, Shelley B, Klein S, Aebischer P, Svendsen CN. 2007. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One 2: e689.
102. Swanson RA, Ying W, Kauppinen TM. 2004. Astrocyte influences on ischemic neuronal death. Curr Mol Med 4: 193-205.
103. Tokumine J, Kakinohana O, Cizkova D, Smith D, Marsala M. 2003. Changes in spinal GDNF, BDNF, and NT-3 expression after transient spinal cord ischemia in the rat. J Neurosci Res 74: 552-561.
104. Valdmanis P, Daoud H, Dion P, Rouleau G. 2009. Recent advances in the genetics of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep 9: 198-205.
105. Van Damme P, Dewil M, Robberecht W, Van Den Bosch L. 2005. Excitotoxicity and amyotrophic lateral sclerosis. Neurodegener Dis 2: 147-159.
106. Van Den Bosch L, Robberecht W. 2008. Crosstalk between astrocytes and motor neurons: What is the message? Exp Neurol 211: 1-6.
107. Vargas MR, Johnson JA. 2010. Astrogliosis in amyotrophic lateral sclerosis: Role and therapeutic potential of astrocytes. Neurotherapeutics 7: 471-481.
108. Vargas MR, Pehar M, Díaz-Amarilla PJ, Beckman JS, Barbeito L. 2008. Transcriptional profile of primary astrocytes expressing ALS-linked mutant SOD1. J Neurosci Res 86: 3515-3525.
109. Vermeiren C, Najimi M, Maloteaux J, Hermans E. 2005. Molecular and functional characterisation of glutamate transporters in rat cortical astrocytes exposed to a defined combination of growth factors during in vitro differentiation. Neurochem Int 46: 137-147.
110. Vermeiren C, Hemptinne I, Vanhoutte N, Tilleux S, Maloteaux J, Hermans E. 2006. Loss of metabotropic glutamate receptor-mediated regulation of glutamate transport in chemically activated astrocytes in a rat model of amyotrophic lateral sclerosis. J Neurochem 96: 719-731.
111. Weishaupt J, Bartels C, Pölking E, Dietrich J, Rohde G, Poeggeler B, Mertens N, Sperling S, Bohn M, Hüther G, Schneider A, Bach A, Sirén AL, Hardeland R, Bähr M, Nave KA, Ehrenreich H. 2006. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 41: 313-323.
112. Wiedau-Pazos M, Goto J, Rabizadeh S, Gralla E, Roe J, Lee M, Valentine J, Bredesen D. 1996. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 271: 515-518.
113. Wijesekera L, Leigh PN. 2009. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 3:4:3.
114. Wong P, Pardo C, Borchelt D, Lee M, Copeland N, Jenkins N, Sisodia S, Cleveland D, Price D. 1995. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14: 1105-1116.
115. Xu L, Shen P, Hazel T, Johe K, Koliatsos V. 2011. Dual transplantation of human neural stem cells into cervical and lumbar cord ameliorates motor neuron disease in SOD1 transgenic rats. Neurosci Lett 494: 222-226.
116. Yamaguchi F, Itano T, Miyamoto O, Janjua NA, Ohmoto T, Hosokawa K, Hatase O. 1991. Increase of extracellular insulin-like growth factor I (IGF-I) concentration following electrolytical lesion in rat hippocampus. Neurosci Lett 128: 273-276.
117. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, Takahashi R, Misawa H, Cleveland DW. 2008. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 11: 251-253.
118. Zagami C, O'Shea R, Lau C, Cheema S, Beart P. 2005. Regulation of glutamate transporters in astrocytes: Evidence for a relationship between transporter expression and astrocytic phenotype. Neurotox Res 7: 143-149.